randomized trial amsacrine rubidazone patients acute promyelocytic leukemia Thirty-nine patients untreated acute promyelocytic leukemia APL rubidazone zorubicin days cytarabine Ara days arm patients amsacrine Amsa days Ara days arm patients Prophylaxis disseminated intravascular coagulation platelet transfusions heparin case leukemic resistance patients second course days rubidazone Amsa arm days Ara complete remission CR consolidation courses drugs induction maintenance therapy years patients arm arm first CR Initial characteristics similar arms arm patients CR hypoplastic death resistance courses arm patients CR early death CNS bleeding case ventricular fibrillation case resistant leukemia courses difference CR rate arms significant arm disease-free survival DFS plateau months confidence interval CI CRs months arm DFS plateau months confidence interval CRs difference DFS significant allografted patients patients CR arm arm results Amsa-Ara combinations inferior anthracycline-Ara combinations treatment APL DFS incidence initial leukemic resistance studies numbers patients 